Once-daily valacyclovir to reduce the risk of transmission of genital herpes. - Wikidata - thesis-toulmin - TriplyDB

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

http://www.wikidata.org/entity/Q34287411

about

HSV-2: in pursuit of a vaccine Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection Third trimester antiviral therapy for preventing recurrent genital herpes at delivery Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future.Targeted DNA mutagenesis for the cure of chronic viral infections A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva A pooled analysis of the effect of condoms in preventing HSV-2 acquisition Transmission probabilities of HIV and herpes simplex virus type 2, effect of male circumcision and interaction: a longitudinal study in a township of South Africa Maternal and neonatal herpes simplex virus infections Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy Detection, quantification and genotyping of Herpes Simplex Virus in cervicovaginal secretions by real-time PCR: a cross sectional survey Multipurpose prevention technologies: the future of HIV and STI protection Phase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Naive and HSV-2-Infected Subjects Incidence of herpes simplex virus type 2 infections in Africa: a systematic review Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding HIV/AIDS epidemiology, pathogenesis, prevention, and treatment Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa.Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection Genital herpes.Sexually transmitted infections among HIV-1-discordant couples.Comparison of the vaginal microbial communities in women with recurrent genital HSV receiving acyclovir intravaginal rings.New concepts in understanding genital herpes.Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model.Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein.The acceptance of HSV-testing partners of HSV-2 seronegative pregnant women.Prevalence and factors associated with herpes simplex virus type 2 infection in patients attending a Baltimore City emergency department.Current status and prospects for development of an HSV vaccine Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.Emerging drugs for varicella-zoster virus infections.Effect of high versus low oral doses of valacyclovir on herpes simplex virus-1 DNA shedding into tears of latently infected rabbits.Can we reduce the spread of HIV infection by suppressing herpes simplex virus type 2 infection?Non-nucleosidic inhibition of Herpes simplex virus DNA polymerase: mechanistic insights into the anti-herpetic mode of action of herbal drug withaferin A Seroprevalence of hepatitis B e antigen (HBe antigen) and B core antibodies (IgG anti-HBcore and IgM anti-HBcore) among hepatitis B surface antigen positive blood donors at a Tertiary Centre in Nigeria.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression.Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial Epidemiological impact of a genital herpes type 2 vaccine for young females.

P2860

Q22306291-71C0C797-22E2-4A7D-BE15-9429222334F4 Q24194490-C76FF05E-E4A7-4170-9CE7-0B660DE15C92 Q24236379-74C4A848-5BE1-4BE7-8618-70F876FF1794 Q24242853-CE61A6A7-2E70-4805-975E-DC7C688A162E Q24246421-9073D1C3-BAB3-4AEC-AF93-205337A395BB Q24600011-FB5260D1-1263-4EEA-BBAE-B2C3FDB9F17F Q24620150-F2F9AC85-DC43-4104-99F2-8F2625718CF9 Q24622287-8E8D5254-2FAD-4500-80E3-C25A8430E1C6 Q24631935-E47C3E49-F86C-41A3-B68F-603C7F460FC0 Q24634285-9DB42A8A-B249-4624-B636-FA0965DD3F4A Q24653520-7FF6D792-F804-4733-AFC9-BF5845DCDF7F Q24672068-E7AA4C06-4307-45CE-96CF-EA45EB839EC4 Q24816175-7BFDE0B4-11E3-4744-9EBB-B4D4C536E7DC Q26827796-75070C57-7508-4760-BDE3-5225BC04E9B1 Q27486108-A1128E14-7FEF-432A-A4E1-FB101AC342D0 Q27690876-96471BA2-79E7-41F3-9FC6-DAD659DC7598 Q28236882-96A4B337-1E3D-41D0-A6E1-34756AD3C4AA Q30356074-86FDEFD1-56CE-4B5B-9677-9AB95C6909E9 Q33336603-E9C4736F-D6B9-4A32-B7BA-6C694BDA77DB Q33395218-86862374-CF98-4A7E-A92B-C6CD342BD533 Q33448071-DFFFA3F1-BDD7-4D10-86B2-F8D817CA2282 Q33518566-6EA40FCF-4BBB-4529-86EA-759F2ADC9154 Q33554048-F9327B93-8268-4496-8CD2-CA4B8D5B01F4 Q33582145-2BFA5D68-FA08-4E53-A4AD-DAC40E5B0E45 Q33638754-46A699F5-1196-4A53-948E-350206229538 Q33710019-7638D032-0767-4215-9244-F4BB9CA0760C Q33724497-22A62E13-77B3-4B30-956E-2342C112E130 Q33774181-A61EE9DA-E43B-42FC-9CDB-9DE85AD1355F Q33921519-88255CBC-6059-4008-A206-F62D8ECBD6AE Q33931016-66F1CCC8-42F5-4323-8404-FE2A9A891F47 Q33993731-597FFBAC-4BE9-4555-98B2-F75B5EC56F88 Q34027426-40414317-C0A0-4D5B-8200-3C8AD7AB1353 Q34135575-BF22E1FC-7536-421A-92B2-5E8F3A65BD36 Q34175582-319156CD-E2BD-40F4-8C21-35ECA35A5931 Q34175625-AB395818-8B3A-4C17-85CF-A04850526311 Q34210772-1119F3F0-EF90-4A43-B4DF-820641B24A81 Q34212799-A05E4747-E37E-4FC3-893B-1A39DDB0FA32 Q34333815-CA620443-D3D1-4018-911A-27398B3E41B3 Q34408313-1B2B1AD8-E523-44F1-A33B-E86C843DD190 Q34446935-07D5D709-57C9-413F-B1B2-E7EF6421CEB2

P2860

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

http://www.wikidata.org/entity/Q34287411

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

@ast

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

@en

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

@nl

type

label

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

@ast

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

@en

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

@nl

prefLabel

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

@ast

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

@en

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

@nl

P1433

Q34287411-D636C964-EB34-4EC6-81BE-2E1AAD340E80

P1476

Q34287411-1E4A5462-064B-4F8E-A4DE-091503BC7E3E

P2093

Q34287411-056C6FC3-CB91-4F7F-8590-FA06740636A7

Q34287411-0A61648C-B704-4D71-900F-B3F44B968CEC

Q34287411-0E494F5F-2460-4F6D-B6B1-492BFF1DEB71

Q34287411-16081B11-366C-486D-AB7E-933BD11015B3

Q34287411-1DB1D950-A99E-490C-A4EE-3F6F44C4DF95

Q34287411-309A4E9E-6336-4621-9F39-40796A8EC7F7

Q34287411-4693F0A6-6BA2-4664-9F85-1776465A7711

Q34287411-96B288D0-3FF3-4550-A48B-4B0EE216FC73

Q34287411-A55C3FD2-5968-4474-8F6F-C985C7FEA23E

Q34287411-BD4C1EFA-7FAC-480F-9DE3-234ED15284E5

P304

Q34287411-10246058-16D0-4CF6-9DC9-FBE0F6D43C64

P31

Q34287411-6572A603-3BC7-4627-8A6D-FA94D4B1C979

P356

Q34287411-857B35A9-A614-4476-8843-6F122F7BDE70

P407

Q34287411-A5432ECE-927F-4130-A198-45D0BC604E75

P433

Q34287411-00B988E7-EF5D-4A4D-B9E2-1AB38491E5F4

P478

Q34287411-3B7088DD-B5F7-434E-A2E9-E4564ED113AA

P50

Q34287411-18B5BC16-C347-4AD5-BA49-C57CE1230FAD

Q34287411-63020418-2F8F-4BFB-9129-D09EB1D0F8CF

Q34287411-E674AF40-0F14-4FD5-85A0-3281BACE6611

P577

Q34287411-1392C16A-3B4C-482B-9CF4-B9873BA1EBC6

P698

Q34287411-0C48545E-6054-4A15-B69A-63320C940D2B

P921

Q34287411-E5A86F2C-EBF5-44BA-B710-367896EE95A4

P356

P1433

The New England Journal of Medicine

P1476

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

@en

P2093

Dereck Tait

http://www.w3.org/2001/XMLSchema#string

Gregory Mertz

http://www.w3.org/2001/XMLSchema#string

Helen A Watson

http://www.w3.org/2001/XMLSchema#string

John M Douglas

http://www.w3.org/2001/XMLSchema#string

Karl R Beutner

http://www.w3.org/2001/XMLSchema#string

Leonid S Stratchounsky

http://www.w3.org/2001/XMLSchema#string

Mauricio Vargas-Cortes

http://www.w3.org/2001/XMLSchema#string

Oliver N Keene

http://www.w3.org/2001/XMLSchema#string

R Ashley Morrow

http://www.w3.org/2001/XMLSchema#string

Raj Patel

http://www.w3.org/2001/XMLSchema#string

P304

11-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA035144

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

350

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14702423

http://www.w3.org/2001/XMLSchema#string

P921